# EDGAR Filing Document

**Accession Number:** 0001764046
**File Stem:** 0001764046-23-000030
**Filing Date:** 2023-3
**Character Count:** 76872
**Document Hash:** ceeca718dc102bc671697704e798f2cc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001764046-23-000030.hdr.sgml**: 20230309

**ACCESSION NUMBER**: 0001764046-23-000030

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 117

**CONFORMED PERIOD OF REPORT**: 20230309

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230309

**DATE AS OF CHANGE**: 20230309

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CLARIVATE Plc
- **CENTRAL INDEX KEY:** 0001764046
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Y9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38911
- **FILM NUMBER:** 23718231

**BUSINESS ADDRESS:**
- **STREET 1:** 1500 SPRING GARDEN STREET
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19130
- **BUSINESS PHONE:** (215) 386-0100

**MAIL ADDRESS:**
- **STREET 1:** 1500 SPRING GARDEN STREET
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Clarivate Analytics PLC
- **DATE OF NAME CHANGE:** 20190108

?xml version="1.0" ? clvt-20230309

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): **March 9, 2023**

**CLARIVATE PLC** 

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Jersey, Channel Islands** | **Jersey, Channel Islands** |
| (State or other jurisdiction of incorporation or organization) | (State or other jurisdiction of incorporation or organization) |
| **001-38911** | **N/A** |
| (Commission File Number) | (I.R.S. Employer Identification No.) |
| **70 St. Mary Axe** | **70 St. Mary Axe** |
| **London EC3A 8BE** | **London EC3A 8BE** |
| **United Kingdom** | **United Kingdom** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) |
| **Not applicable** | **Not applicable** |
| (Zip Code) | (Zip Code) |

---

**(44) 207-433-4000** 

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Ordinary Shares | CLVT | New York Stock Exchange |
| 5.25% Series A Mandatory Convertible Preferred Shares, no par value | CLVT PR A | New York Stock Exchange |
| Series B Preferred Stock Purchase Rights | - | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01. Regulation FD Disclosure.**

**Clarivate Investor Day Conference**

As previously announced, Clarivate Plc (the "Company" or "Clarivate") is hosting an Investor Day conference 9:00 a.m. ET, on Thursday, March 9, during which management is providing an update on the business. All are invited to listen to the event and view the presentation via the live video stream on the Clarivate Investor Relations website at http://ir.clarivate.com/. The virtual event can also be accessed directly by visiting https://investorday2023.virtualevent.page/. A replay will be available on the investor relations section of the Company's website. See Exhibit 99.1 for certain presentations that Company management is delivering at the Investor Day conference.

**2023 Outlook**

On March 9, 2023, Clarivate announced that it reaffirmed its guidance previously announced on March 1, 2023 for the year ending December 31, 2023.

The full year outlook presented below assumes no further acquisitions, divestitures, or unanticipated events.

---

| | |
|:---|:---|
| | **2023 Outlook** |
| Revenues | $2.63B to $2.73B |
| Organic Revenue Growth | 2.75% to 3.75% |
| Adjusted EBITDA | $1.10B to $1.16B |
| Adjusted EBITDA Margin | 42.0% to 42.5% |
| Adjusted Diluted EPS | $0.75 to $0.85 |
| Free Cash Flow | $450M to $550M |

---

Adjusted Diluted EPS for 2023 is calculated based on approximately 740 million fully diluted weighted average shares outstanding.

See Exhibit 99.2 for important disclosures and reconciliations of these financial measures to the most directly comparable U.S. generally accepted accounting principles ("GAAP") measure.

**Forward-Looking Statements**

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management's current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like "aim," "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "likely," "may," "might," "plan," "potential," "predict," "project," "see," "seek," "should," "strategy," "strive," "target," "will," and "would" and similar expressions, and variations or negatives of these words. Examples of forward-looking statements include, among others, statements we make regarding: guidance outlook and predictions relating to expected operating results, such as revenue growth and earnings; strategic actions such as acquisitions, joint ventures, and dispositions, including the anticipated benefits therefrom, and our success in integrating acquired businesses; anticipated levels of capital expenditures in future periods; our ability to successfully realize cost savings initiatives and transition services expenses; our belief that we have sufficient liquidity to fund our ongoing business operations; expectations of the effect on our financial condition of claims, litigation, environmental costs, the impact of inflation, the impact of foreign currency fluctuations, the COVID-19 pandemic and governmental responses thereto, international hostilities, contingent liabilities, and governmental and regulatory investigations and proceedings; and our strategy for customer retention, growth, product development, market position, financial results, and reserves. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are difficult to predict and many of which are outside of our control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed under the caption "Risk Factors" in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission ("SEC"). However, those factors should not be considered to be a complete statement of all potential risks and uncertainties. Additional risks and uncertainties not known to us or that we currently deem immaterial may also impair our business operations. Forward-looking statements are based only on information currently available to our management and speak only as of the date of this communication. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of

new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Please consult our public filings with the SEC or on our website at www.clarivate.com.

**No Incorporation by Reference**

The information in this Item 7.01, including Exhibits 99.1 and 99.2 furnished herewith, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

**Item 9.01. Financial Statements and Exhibits**

Furnished as Exhibit 99.1 to this Report on Form 8-K are certain presentations that Company management is delivering at the Investor Day conference on March 9, 2023. Furnished as Exhibit 99.2 to this Report on Form 8-K is information regarding non-GAAP financial measures presented herein.

**(d) Exhibits**

---

| | |
|:---|:---|
| **No.** | **Description** |
| 99.1 | <u>[Investor Day (March 9, 2023)](ex991clvtinvestorday.htm)</u> |
| 99.2 | <u>[Information Related to Non-GAAP Financial Measures and Reconciliations to GAAP Measures](ex992clvtinvestordayappe.htm)</u> |
| 104 | Cover page of this Current Report on Form 8-K formatted in Inline XBRL. |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | | **CLARIVATE PLC** |
| Date: March 9, 2023 | By: | /s/ Jonathan Collins |
|  | Name: | Jonathan Collins |
|  | Title: | Executive Vice President & Chief Financial Officer |

---

## Exhibit 99.1

![](ex991clvtinvestorday001.jpg)

Investor Day March 9, 2023

------

![](ex991clvtinvestorday002.jpg)

2 Mark Donohue VP Investor Relations Opening Remarks

------

![](ex991clvtinvestorday003.jpg)

3 Safe Harbor Statement and Non-GAAP Financial Measures Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management's current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like "aim," "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "likely," "may," "might," "plan," "potential," "predict," "project," "see," "seek," "should," "strategy," "strive," "target," "will," and "would" and similar expressions, and variations or negatives of these words. Examples of forward-looking statements include, among others, statements we make regarding: guidance outlook and predictions relating to expected operating results, such as revenue growth and earnings; strategic actions such as acquisitions, joint ventures, and dispositions, including the anticipated benefits therefrom, and our success in integrating acquired businesses; anticipated levels of capital expenditures in future periods; our ability to successfully realize cost savings initiatives and transition services expenses; our belief that we have sufficient liquidity to fund our ongoing business operations; expectations of the effect on our financial condition of claims, litigation, environmental costs, the impact of inflation, the impact of foreign currency fluctuations, the COVID-19 pandemic and governmental responses thereto, international hostilities, contingent liabilities, and governmental and regulatory investigations and proceedings; and our strategy for customer retention, growth, product development, market position, financial results, and reserves. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are difficult to predict and many of which are outside of our control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed under the caption "Risk Factors" in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission ("SEC"). However, those factors should not be considered to be a complete statement of all potential risks and uncertainties. Additional risks and uncertainties not known to us or that we currently deem immaterial may also impair our business operations. Forward-looking statements are based only on information currently available to our management and speak only as of the date of this communication. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Please consult our public filings with the SEC or on our website at www.clarivate.com. Non-GAAP Financial Measures This presentation contains financial measures which have not been calculated in accordance with United States generally accepted accounting principles ("GAAP"), including Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Diluted EPS, Free Cash Flow, and Organic Revenues because they are a basis upon which our management assesses our performance, and we believe they reflect the underlying trends and indicators of our business. Although we believe these measures may be useful for investors for the same reasons, these financial measures should not be considered as an alternative to GAAP financial measures as a measure of the Company's financial condition, profitability , performance and liquidity. In addition, these financial measures may not be comparable to similar measures used by other companies. At the Appendix to this presentation, we provide further descriptions of these non-GAAP measures and reconciliations of these non-GAAP measures to the corresponding most closely related GAAP measures. Industry and Market Data In this presentation we refer to certain information and statistics from third-party sources. Although we believe that these sources are reliable, we have not independently verified the accuracy or completeness of such third-party sources and disclaim any liability with respect to the data therein that have been included in this presentation, and cannot guarantee their accuracy or completeness.

------

![](ex991clvtinvestorday004.jpg)

Agenda 4 01. Our DNA Jonathan Gear Chief Executive Officer 02. Our Investment Thesis 03. Our Core Competencies 04. Our Operating Model 05. Our Segments Gordon Samson Chief Product Officer Academia & Government Panelists Life Sciences & Healthcare Intellectual Property 06. Our Strategy Jonathan Gear Chief Executive Officer 07. Our Current Position 08. Our Growth Plan Jonathan Collins Chief Financial Officer 09. Our Financial Outlook 10. Q&A All

------

![](ex991clvtinvestorday005.jpg)

5 Life Sciences & Healthcare Video

------

![](ex991clvtinvestorday006.jpg)

6 Jonathan Gear Chief Executive Officer

------

![](ex991clvtinvestorday007.jpg)

------

![](ex991clvtinvestorday008.jpg)

8 Undergoing operating transformation that will prioritize reinvestment in product innovation to accelerate growth Last Six Months • Transitioning leadership team • Pivoted operating model to drive ownership and leverage shared scale • Assessed growth potential and developed growth acceleration framework • Acquired businesses to build scale and end-to-end capabilities • Integrated acquisitions and delivered cost synergies • Navigated global pandemic Next Three Years • Invest in product innovation to drive growth and reinvigorate market leading solutions • Increase organic growth and cash flow to strengthen balance sheet • Drive shareholder value through disciplined capital allocation NYSE Listing to Fall 2022

------

![](ex991clvtinvestorday009.jpg)

9 Our DNA 01

------

![](ex991clvtinvestorday010.jpg)

10 We are connected by a shared purpose, vision, mission and values To elevate the ideas that will benefit everyday life Purpose Why we exist To fuel the world's greatest breakthroughs by harnessing the power of human ingenuity Vision What we're working towards To advance the success of people and organizations through transformative intelligence and trusted partnership Mission How we'll get there We challenge the status quo, pursuing continuous performance improvements and aiming for greatness and customer delight in all we do We aim for greatness Trust is built on actions: We act with integrity and are accountable to ourselves, our colleagues, our customers and our communities We own our actions We work together in respectful partnership with our customers, colleagues and shareholders which is our evergreen source of sustainability and success We value every voice Values What's important to us

------

![](ex991clvtinvestorday011.jpg)

11 We are committed to sustainability, diversity, equity, and inclusion We are in the top 10% for sustainability in our industry for 2020-2022 according to the S&P Global ESG Index 80M+ Patients supported through chronic diseases by improving understanding of their medicines 130M+ Students use our solutions to enhance their learning and research experience 55% Of companies ranked in the Dow Jones Sustainability World Index work in partnership with us Impacting outcomes in partnership with our customers Initiated Council for Inclusion and Diversity at Clarivate chaired by the CEO to drive diversity efforts Enterprise-wide colleague resource groups focused on promoting inclusion 60/40 gender diversity on our executive leadership team and striving towards equal gender balance at all levels Promoting diversity and inclusion throughout our organization

------

![](ex991clvtinvestorday012.jpg)

12 We are global thought leaders across the innovation ecosystem with 11,000+ colleagues in 40+ countries 3K+ Americas 3K+ EMEA 5K+ APAC Academia & Government Life Sciences & Healthcare Intellectual Property Identifying cutting edge innovation Citation Laureates™ Identifying potential Nobel Prize winners of tomorrow Drugs to Watch™ Predicting blockbuster drugs which will benefit millions of patients Top 100 Global Innovators™ Recognizing cutting-edge innovators defining their respective sectors

------

![](ex991clvtinvestorday013.jpg)

13 Our Investment Thesis 02

------

![](ex991clvtinvestorday014.jpg)

14 Best of both worlds information services portfolio • Serve one primary industry vertical • Solutions use shared capabilities, infrastructure and expertise Academia & Government Life Sciences & Healthcare Intellectual Property We serve three adjacent innovation-based industries that are driven by ever-increasing demand for insights Horizontal Info Services Companies Vertical Info Services Companies • Serve numerous industry verticals • Portfolio of solutions with disparate capabilities, infrastructure and expertise Scale Synergies Across Categories Mission Critical Solutions Acyclic Markets

------

![](ex991clvtinvestorday015.jpg)

15 Multiple reinforcing dynamics combine, presenting a compelling opportunity to drive profitable and sustainable growth Secular Growth Markets Economically Insulated • x Our markets are expanding, driven by innovation with long runway for growth Resilient markets which have outperformed in periods of economic downturn Industry gold standard solutions embedded in customer workflows Recurring information services compounder poised to accelerate organic growth and financial returns Mission Critical Solutions Robust Business Model

------

![](ex991clvtinvestorday016.jpg)

16 Secular Growth Markets \| Our markets are expanding, driven by innovation with long runway for growth ~6% SAM Growth² > Accelerating HC data proliferation and demand for real world evidence Increasing regulatory and market access requirements Growing research funding & increasingly multi-disciplinary fields Growing academic operating model complexity Increasing patent/trademark filing Increasing R&D spend to drive competitive innovation Academia & Government Life Sciences & Healthcare Intellectual Property > Acyclic knowledge economy sectors Aligned with global economic trends Complex value chain requires efficient transfer of insights Data and analytics driven > > ~4%¹ ~6%¹~10%¹ 1 Historical serviceable addressable market growth per company estimates. ² Serviceable Addressable Market.

------

![](ex991clvtinvestorday017.jpg)

17 Economically Insulated \| Resilient markets which have outperformed in periods of economic downturn 1 Percentage of FY22 Clarivate revenue. Sources: World Bank, Statista, WIPO. Dotcom Bubble (2000-2001) Global Financial Crisis (2008-2009) Global Patent GrantsGLOBAL GDP Baseline YoY Change Scientific & Technical Journal Articles US Pharmaceutical R&D Expenditure (1%) (5%) +6% +11ppt (2%) +3ppt +4% +9ppt +4% +5ppt +15% +16ppt +4% +5ppt Academia & Government ~48%¹ \| Life Sciences & Healthcare ~17%¹ \| Intellectual Property ~35%¹ Change vs. GDPYoY Change

------

![](ex991clvtinvestorday018.jpg)

18 Mission Critical Solutions \| Industry gold standard solutions embedded in customer workflows 1 World's largest publisher-neutral citation database. ² Hyperion Global Partners' 2022 MarketView. IPfolio recognized as a market leader in IP management by MarketView² ProQuest One Literature: Charleston Advisor readers choice best content Patented algorithm for drug timeline and success rates, covering over 19K drug projects ProQuest One™ Academic Web of Science™ Alma™ Cortellis™ Dialog™ HDS Derwent™ CompuMark™ IPfolio™ Academia & Government Life Sciences & Healthcare Intellectual Property 320M longitudinal real-world data patient records2B citations in world's largest curated citation database¹ 140M curated trademark records in CompuMark™ 003M curated pharmacological studies in Cortellis Drug Discovery 1.5B scholarly and academic records used for research, teaching and learning 101M editorially enhanced and curated patent records

------

![](ex991clvtinvestorday019.jpg)

19 Robust Business Model \| Recurring information services compounder poised to accelerate organic growth and financial returns >90% renewal rates >40% profit margin² ~50% FCF conversion ~80% recurring revenue¹ 1 Includes subscription and re-occurring revenue types. ² Adj. EBITDA.

------

![](ex991clvtinvestorday020.jpg)

20 Our Core Competencies 03

------

![](ex991clvtinvestorday021.jpg)

21 Clarivate was built with four transformational acquisitions extending customer value across our core markets 2016 2020 2020 Intellectual Property Intellectual Property 2021 Life Sciences & Healthcare Life Sciences & Healthcare Academia & Government Academia & Government Acquired foundation capabilities across our three core markets End-to-end capabilities across the Life Sciences & Healthcare innovation lifecycle End-to-end capabilities across the Intellectual Property lifecycle End-to-end capabilities to support A&G research and resource management needs SCIENTIFIC

------

![](ex991clvtinvestorday022.jpg)

22 An indispensable partner, deeply entrenched across the global innovation ecosystem Countries in which customers benefit from our data, software and expert insight ~150+ ~99% Of the world's top 400 universities use our solutions to accelerate research and enhance education¹ 100% Of the world's top pharma, medtech and biotech companies rely on us to improve patient outcomes² Of the world's top 50 R&D companies work with us to accelerate innovation³ ~96% 1 Top 400 universities (QS world university rankings). ² Top 30 pharma (Drug Discovery Trends). Top 20 medical device (Greenlight Guru). Top 10 biotech (Investopedia). ³ Top 50 based on R&D spend (European Union).

------

![](ex991clvtinvestorday023.jpg)

23 Our best-in-class data powers our solution and service capabilities across our segments 5+ million Dissertations 245+ million Journal articles 2.4+ billion Bibliographic records 1.8+ million E-books 7+ billion Digital pages 2+ billion Citations 3+ million Molecular interactions 48+ billion Patient claims & EHR records 150+ million Patent documents 9.1+ million IP law cases 141+ million Trademark records Enriched Data Provide comprehensive, curated content collections Analytics & Insights On demand predictive analytics capabilities to inform decision making Workflow Solutions Automate workflow SaaS to enable decisions and manage resources Expert Services Support business critical regulatory and compliance activities

------

![](ex991clvtinvestorday024.jpg)

24 Our capabilities are underpinned by market-leading assets serving a diverse range of personas across the innovation lifecycle CommercializationKnowledge & Learning Discover & Research Protect & PublishMarket Academia & Government Life Sciences & Healthcare Intellectual Property Healthcare Business Insights STEM DatabaseEbook Central ProQuest One™ Academic Rialto™ Ebook Central Academic Video Online Leganto™ Web of Science™ Web of Science™ Primo™ Summon™ Alma™ Pivot™ Polaris™ Cortellis™ Derwent™ Consultancy Web of Science™ Cortellis™ Consultancy Dialog™ Derwent™ Esploro™ Converis™ InCites™ ScholarOne™ Derwent™ CompuMark™ Darts-ip™ CPA Global Derwent™ CompuMark™ Darts-ip™ CPA Global Derwent™ CompuMark™ CPA Global Consultancy InCites™ Derwent™ CPA Global Journal Citation Reports Healthcare Data Solutions Patient Connect™ Dialog™ Derwent™CompuMark™ Consultancy Enriched Data \| Analytics & Insights \| Workflow Solutions \| Expert Services IPfolio™ IPfolio™ FoundationIP™ FoundationIP™

------

![](ex991clvtinvestorday025.jpg)

25 Our mission critical solutions power our customers through the innovation lifecycle ¹ FY22 financial information. Empowering universities to educate students and conduct research efficiently through the curated collections of academic content Enabling life sciences companies to ensure regulatory compliance and deliver safe and efficacious medicines to patients faster Powering discovery, research and learning across academic libraries through critical software and infrastructure solutions Enabling organizations to mitigate risk in IP protection and navigate the complex IP system through deep domain expertise and software Universities \| Research Institutes \| Libraries \| Govt. Agencies \| Pharmaceuticals \| MedTech \| BioTech \| Corporate IP Departments \| Law Firms ~99% ~99% ~97% ~97% ProQuest One Renewal Rate¹ Academia & Government Dialog Renewal Rate¹ Life Sciences & Healthcare Alma Renewal Rate¹ Academia & Government IP Renewals Retention Rate¹ Intellectual Property Knowledge & Learning Discover & Research Protect & Publish Commercial -ization Enriched Data Analytics & Insight Workflow Solutions Expert Services

------

![](ex991clvtinvestorday026.jpg)

26 Our Operating Model 04

------

![](ex991clvtinvestorday027.jpg)

27 An operating structure that enables ownership and unlocks scale across Clarivate Growth, resource allocation and financial return ownership Academia & Government Life Sciences & Healthcare Intellectual Property Growth, resource allocation and financial return ownership Growth, resource allocation and financial return ownership Content, Operations and Solutions Information Technology Commercial Channels Customer Experience Talent, Culture and Brand Product Management Product Engineering Sales & Marketing Expert Services Product Management Product Engineering Sales & Marketing Expert Services Product Management Product Engineering Sales & Marketing Expert Services

------

![](ex991clvtinvestorday028.jpg)

28 A&G Publications LS&H Data IP Information Enriched Data Analytics & Insights Workflow Software (SaaS) Expert Services Data Fusion Market Specific Solutions Serving Use Cases Across the Innovation Cycle Learning \| Research \| Research Policy and Assessment Academia & Government Drug Development \| Regulation and Safety \| Commercialization Life Sciences & Healthcare Protection \| Management \| Risk Mitigation \| Decision Support Intellectual Property Shared Content Shared Technology Scale across our core markets, powering innovation from funding through to research, development and commercialization Shared Commercial Channels Achieving scale across core markets by bringing together our assets, enabling segment specific use cases across the innovation cycle

------

![](ex991clvtinvestorday029.jpg)

29 Shared Content \| Integrated data powers our solutions, unlocking high value use cases across our end markets Data Sources Data Fusion End Markets 2B+ citations 245M+ journal articles 1B+ newspaper articles 3M+ molecular interactions 150M+ patent documents 5M+ chemical indexed inventions 160M+ biological sequences 3M+ pharmacology records 550K+ clinical trials 250K+ regulatory documents 26% of Derwent customers use A&G / LS&H solutions 39M+ citations in Derwent Patent Citation Index 190K+ WoS literature searches conducted in Derwent 55k+ queries of Derwent Patent data within Cortellis 145K+ page views of WoS literature within Cortellis 70% increase in NPS for users with WoS linked data² 1.5M+ queries of Derwent patent data within WoS¹ 100%+ increase in WoS sessions accessing Derwent data 24% of LS&H customers also purchase A&G products A&G Solutions LS&H Solutions IP Solutions A&G Publications LS&H Data IP Information ¹ Web of Science. ² Net Promoter Score.

------

![](ex991clvtinvestorday030.jpg)

30 Shared Technology \| Enabling customer value creation through unified technology platforms Interconnected Data Insights and Analytics Scalable Solutions Next Gen Solutions Data Infrastructure Common data stores and data lakes enhancing connectivity between distinct data sets across an array of solutions Data Science Organization wide, common machine learning and AI models driving insights generation Scalable & Interoperable Products Common platforms that scale efficiently, and accelerate delivery of our solutions to market Technology Driven Innovation Leverage next generation technologies such as blockchain and natural language models Shared technology investments accelerate R&D solution innovation across our three segments

------

![](ex991clvtinvestorday031.jpg)

31 Shared Commercial Channels \| Unleashing the power of our full set of solutions to exceed market growth: Top 5 Pharma customer case study Improving patient outcomes through our solutions set Academia & Government Intellectual Property Derwent™ Darts-ip™ CompuMark™ Renewals Inprotech™ Life Sciences & Healthcare Cortellis™ Consultancy Dialog™MetaCore™ Real World Data BioWorld™ Web of Science™ EndNote™ Ebook Central™ Resulting in double digit growth in key customer accounts $15M $5M $0 $10M FY22FY20 FY21 > 15%¹ A&G IPLS&H 1 FY20-22 CAGR.

------

![](ex991clvtinvestorday032.jpg)

32 Scale \| Leveraged our shared services to achieve significant cost synergies and scale ~$100M ~$75M ~$30M ~$100M Streamline and consolidation Realized cost synergies ~$300M Content Operations • Cross segment AI enabled editorial operations and quality assurance Technology Infrastructure • Datacenter and cloud services unification • ERP and CRM platform consolidation Customer Care • Streamlined customer workflows • Consolidation of systems and processes SCIENTIFIC

------

![](ex991clvtinvestorday033.jpg)

33 Accelerated compound returns driven by reinvestment into high-potential growth areas Secular Growth Markets Significant Operating Leverage Attractive Cash Flow Engine Disciplined Capital Allocation Shared Content Shared Technology Shared Commercial Channels Operating Model Driving Accountability and Leveraging Shared Scale Scale Across Core Markets ~80% Recurring Revenue ~50% FCF Conversion >90% Renewal Rates >40% Profit Margin

------

![](ex991clvtinvestorday034.jpg)

34 Gordon Samson Chief Product Officer

------

![](ex991clvtinvestorday035.jpg)

35 Our Segments 05

------

![](ex991clvtinvestorday036.jpg)

36 Dr. Nandita Quaderi Editor-in-Chief Web of Science Jim Holmes SVP Sales Academia & Government Advance research excellence and student success to accelerate real-world outcomes

------

![](ex991clvtinvestorday037.jpg)

37 Academia & Government \| Our largest segment with considerable market opportunity ~99% Of the world's top 400 universities use our solutions to accelerate research and enhance education² ~48% Pct. of Clarivate Revenue¹ ~$7B Serviceable Addressable Market³ Market Growth³ ~4% 1 FY22 revenue. ² Top 400 universities (QS world university rankings). ³ Clarivate analysis.

------

![](ex991clvtinvestorday038.jpg)

Our customers face accelerating market trends which our solution set can help address 38 Complexity of managing research process is increasing across academia and government Increasing demand to demonstrate research return on investment for research Changing operating model for universities and research- intensive organizations Growing research funding & increasingly multi-disciplinary fields Growing academic operating model complexity

------

![](ex991clvtinvestorday039.jpg)

Workflow Software Solutions Software tools to manage academic resources and services, connect users and support research publication Content Aggregation Provide comprehensive content collections to institutions in a cost- effective manner 39 We offer a diverse range of solutions across our customer segment advancing research excellence and student success Key Solutions Research and Analytics Analyze and explore the academic research landscape and manage research information Web of Science™ EndNote™InCites™ Ebook Central™ Rialto™ Alma™ ProQuest One Academic™ Polaris™

------

![](ex991clvtinvestorday040.jpg)

40 We help academic and government institutions advance knowledge to build a better world Drive research excellence across institutions Empower researchers to tackle today's global challenges Improve operational efficiency and effectiveness Customers

------

![](ex991clvtinvestorday041.jpg)

41 Opportunity to expand our content and solutions throughout the non- native English speaking world 41

------

![](ex991clvtinvestorday042.jpg)

42 Dr. Rob Poolman SVP Product Tom Halliday SVP Sales Life Sciences & Healthcare Empowering life sciences and healthcare organizations to create a healthier tomorrow

------

![](ex991clvtinvestorday043.jpg)

1 FY22 revenue. ² Top 30 pharma companies (Drug Discovery Trends). Top 20 medical device companies (Greenlight Guru). Top 10 biotech companies (Investopedia). ³ Clarivate analysis. 43 Life Sciences & Healthcare \| High growth market driven by research and development ~17% Pct. of Clarivate Revenue¹ Market Growth³ ~10%~100% Of the top pharma, medtech and biotech rely on us to improve patient outcomes² ~$12B Serviceable Addressable Market³

------

![](ex991clvtinvestorday044.jpg)

Our customers face accelerating market trends which our solution set can help address 44 Real world evidence drives the value chain as therapeutic complexity increases Value-based care models call for correlated data and new analytics Growing burden to manage regulatory oversight and compliance obligations Accelerating HC data proliferation and demand for real world evidence Increasing regulatory requirements

------

![](ex991clvtinvestorday045.jpg)

Commercialization Effectively inform commercial and launch strategy and set pricing for optimal reimbursement 45 Our portfolio spans across the drug and device lifecycle from R&D to commercialization Key Solutions Regulatory and Safety Efficiently monitor drug safety issues and adhere to the latest global regulatory protocols Research and Development Develop new drugs and medical devices from discovery through to clinical trials Cortellis™ MedTech 360™MetaCore™ Fingertip Formulary™ Patient Connect™ Dialog™ HDSBioWorld™ Adaptive

------

![](ex991clvtinvestorday046.jpg)

46 We empower life sciences and healthcare organizations to create a healthier tomorrow Customers Drive asset and portfolio value Measure, protect and grow position Advance innovative candidates Accelerate path to patients

------

![](ex991clvtinvestorday047.jpg)

47 Opportunity to extend our capabilities beyond data and insights to include mission critical workflow software solutions

------

![](ex991clvtinvestorday048.jpg)

48 Jack White SVP Product Irmina Stroud SVP Sales Intellectual Property Empowering customers to unlock the full potential of IP

------

![](ex991clvtinvestorday049.jpg)

49 Intellectual Property \| Cornerstone of innovation fueling commercialization and real-world outcomes ~35% Pct. of Clarivate Revenue¹ Market Growth³ ~6%~96% Of top 50 R&D companies work with us to accelerate the pace of innovation² ~$5B Serviceable Addressable Market³ 1 FY22 revenue. ² Top 50 based on R&D spend (European Union). ³ Clarivate analysis.

------

![](ex991clvtinvestorday050.jpg)

Our customers face accelerating market trends which our solution set can help address 50 Increasingly complex IP network requiring better collaboration and technology AI/ML and predictive analytics are making inroads into the IP process Managing IP as a business asset is becoming increasingly complex Increasing R&D spend to drive competitive innovation Increasing patent/trademark filing

------

![](ex991clvtinvestorday051.jpg)

51 We are a partner of choice for IP management and decision support needs of innovation-driven organizations and law firms Key Solutions Derwent™ RenewalsInnography™ IPfolio™CompuMark™ Darts-ip™ Inprotech™incoPat FoundationIP™ Patent and Trademark Maintenance Solutions Supporting paralegal and admin tasks throughout the IP protection and maintenance process Patent and Trademark Management Create a structured environment for the effective protection and management of global IP assets Patent and Trademark Intelligence Support mission critical decisions around IP protection, risk and value creation

------

![](ex991clvtinvestorday052.jpg)

Enable critical IP decision- making throughout the innovation and brand lifecycle Improve practice profitability and enhance customer services 52 We help customers establish, protect and manage their intellectual property Customers Enhance IP management efficiency and effectiveness

------

![](ex991clvtinvestorday053.jpg)

53 Unique opportunity to connect and lead the IP ecosystem by combining insights, domain expertise and new technologies to enhance productivity and collaboration across the IP process

------

![](ex991clvtinvestorday054.jpg)

Investor Day 2023 Break

------

![](ex991clvtinvestorday055.jpg)

55 Jonathan Gear Chief Executive Officer

------

![](ex991clvtinvestorday056.jpg)

56 Our Strategy 06

------

![](ex991clvtinvestorday057.jpg)

57 We are evolving from a data centric solutions provider… …to an insights-driven strategic partner to support the innovation lifecycle

------

![](ex991clvtinvestorday058.jpg)

58 Principles & Values Innovation redefined \| Unparalleled expertise \| Sustainable impact We own our actions \| We aim for greatness \| We value every voice Key Pillars Growth acceleration framework: Intelligence that you can trust to transform the world Execute customer-centric go-to-market model positioning our full business value Leverage interconnected data for customer personas via accessible solutions & software-enabled content Go beyond data delivering insights & predictive analytics to unleash innovation Enable business processes and decision support through essential workflow solutions Serve as a trusted partner, offering value-add services & strategic guidance 1 2 3 4 5

------

![](ex991clvtinvestorday059.jpg)

59 Our Current Position 07

------

![](ex991clvtinvestorday060.jpg)

60 Significant opportunity to expand organic growth across our three segments Segments FY20-22 Growth Rate² Market Growth Rate³ Growth Opportunity $2.7B¹ ~3% ~6% ~3% ~2%Academia & Government ~4% ~2% ~6%Life Sciences & Healthcare ~10% ~4% ~3%Intellectual Property ~6% ~3% 1 FY22 revenue. ² Historical growth based on 3-year CAGR 2020PF – 2022A pro forma for acquisitions and divestitures at constant currency. ³ Clarivate analysis.

------

![](ex991clvtinvestorday061.jpg)

Realizing our growth opportunity in Academia & Government 61 Academia & Government \| Realizing our growth opportunity through content, analytics and use case expansion Research and Analytics Content Aggregation Workflow Software Solutions Historical Growth¹ ~2% Market Growth ~4% Growth Opportunity ~2% + Capability Breakdown Performance ¹ Historical growth based on 3-year CAGR 2020PF – 2022A pro forma for acquisitions and divestitures at constant currency. Deliver unparalleled research insights and analytical solutions Maintain and expand best-in-class content aggregation portfolio Expand our multichannel approach to serve a diverse academic ecosystem Achieving/exceeding Close to market growth Underperforming Performance to Market Growth Rates

------

![](ex991clvtinvestorday062.jpg)

Realizing our growth opportunity in Life Sciences & Healthcare 62 Life Sciences & Healthcare \| Moving up the value chain through integrated platforms and enhanced content ¹ Historical growth based on 3-year CAGR 2020PF – 2022A pro forma for acquisitions and divestitures at constant currency. Accelerate drug and device R&D through AI/ML powered solutions Capitalize on increasing emphasis from regulatory authorities on drug safety Move up the value chain through RWD commercialization platform solutions Research and Development Regulatory and Safety Commercialization Historical Growth¹ ~6% Market Growth ~10% Growth Opportunity ~4% + Capability Breakdown Performance Achieving/exceeding Close to market growth Underperforming Performance to Market Growth Rates

------

![](ex991clvtinvestorday063.jpg)

63 Intellectual Property \| Driving improvement through connected intelligence and use case expansion Historical Growth¹ ~3% Market Growth ~6% Growth Opportunity ~3% + ¹ Historical growth based on 3-year CAGR 2020PF – 2022A pro forma for acquisitions and divestitures at constant currency. Realizing our growth opportunity in Intellectual Property Strengthen core search capabilities and expand IP intelligence to new use cases Enhance software integrating experts, insights and collaboration solutions Unify technology and expert services to drive efficiency in global filing practices Patent and Trademark Intelligence Patent and Trademark Management Patent and Trademark Maintenance Solutions Capability Breakdown Performance Achieving/exceeding Close to market growth Underperforming Performance to Market Growth Rates

------

![](ex991clvtinvestorday064.jpg)

64 Realizing our revenue growth opportunity across our three segments by FY25 Segments FY20-22 Growth Rate² Growth Improvement FY25 Growth Rate $2.7B¹ ~3% ~3% ~6% ~2%Academia & Government ~2% ~4% ~6%Life Sciences & Healthcare ~4% ~10% ~3%Intellectual Property ~3% ~6% 1 FY22 revenue. ² Historical growth based on 3-year CAGR 2020PF – 2022A pro forma for acquisitions and divestitures at constant currency.

------

![](ex991clvtinvestorday065.jpg)

65 Jonathan Collins Chief Financial Officer

------

![](ex991clvtinvestorday066.jpg)

66 Our Growth Plan 08

------

![](ex991clvtinvestorday067.jpg)

67 Our growth plan will enable us to achieve and exceed market growth rates Total Addressable Market (TAM) Size of the total innovation lifecycle management market Serviceable Addressable Market (SAM) Size of the innovation lifecycle management market served by our current solutions, which we are actively expanding~$25B SAM³ 6% Growth Rate >100B TAM³ 10% Growth Rate ~$2.7B Revenue¹ 3% Growth Rate² Key 1 FY22 revenue. ² FY20PF-22A CAGR. ³ Clarivate analysis. Actions to achieve market growth rates Actions to exceed market growth rates

------

![](ex991clvtinvestorday068.jpg)

68 Insights and predictive analytics Interconnected data Business processes and decision support Value-add services Utilizing our growth levers to achieve and exceed market growth rates Life Sciences & Healthcare Intellectual Property Actions to achieve market growth rates Actions to exceed market growth rates Key Customer-centric go-to-market model Academia & Government 1 2 3 4 5 Strategic Growth Pillars

------

![](ex991clvtinvestorday069.jpg)

Achieve Growth 69 Academia & Government \| Returning to growth in underperforming areas Improving performance through our customer- centric go-to-market model and value-add services Returning to market growth rates in Research & Analytics and Workflow Software Solutions Web of Science Growing revenue by selling best-in-class Web of Science research discovery and analytics portfolio into Corporates and leveraging custom data solutions Research and Analytics Increasing retention with our customers by combining ProQuest and Web of Science solutions Alma™Web of Science™ Enhanced Content Leverage and interconnect new, distinct content sources to establish more competitive differentiation Resource Analytics Develop decision support capabilities enabling academic administrators to maximize educational resources Leganto™

------

![](ex991clvtinvestorday070.jpg)

Best-in-class Workflow Solutions Incorporation of next generation features and third- party integrations to improve resource management Premier Content Marketplace Grow content portfolio and establish the premier content marketplace to accelerate knowledge transfer 70 Academia & Government \| Actioning our growth opportunity across high performing areas Vega™Primo™ Rialto™ Accelerating the capture of market opportunities Driving growth and expanding SAM in high performing areas Exceed Growth Innovation Commercialization Cross-sell IP lifecycle platforms to enhance research commercialization across A&G customers Expert Services Expansion Grow innovation-focused consulting services to inform governmental R&D policy and university strategy Summon™

------

![](ex991clvtinvestorday071.jpg)

71 Academia & Government \| Pillars in action Advising senior leadership team of a top-tier US research university on fastest growing research disciplines to inform hiring and funding strategy to elevate university reputation Providing country-wide access to bibliometric analytics and new content sets to European academic consortium to accelerate research Implementing country-wide engagement and workflow software suite to maximize resource usage and enhance operational efficiency

------

![](ex991clvtinvestorday072.jpg)

Healthbase Fingertip Formulary™ Integrated Solutions Unite and optimize commercialization and market access solutions to enhance user value proposition Enhanced Content Interconnect complementary Life Sciences & Healthcare data to provide AI/ML powered insights 72 Life Sciences & Healthcare \| Returning to growth in underperforming areas Embedded Services Layer Further integrate services into wider product and data solutions to increase revenue pull through Strategic Partner Leveraging insights from our connected data stores and lakes to deliver strategic guidance to C-suite stakeholders Improving performance through value-add services Returning to market growth rates in commercialization Achieve Growth

------

![](ex991clvtinvestorday073.jpg)

Real World Data Solutions Drug Safety Triager Regulatory Workflow and Insights Combining data, insights and services to provide holistic regulatory solutions, enabling global compliance Patient Cohorts Identifying patient populations to prioritize R&D and commercialization strategies 73 Life Sciences & Healthcare \| Actioning our growth opportunity across high performing areas Accelerating the capture of market opportunities Driving growth and expanding SAM in high performing areas Next Gen Drug Safety and Pharmacovigilance Partnering with customers to streamline regulatory compliance across the drug safety workflow Real World Data Solutions Improve accessibility of real world data and delivering critical insights through tech-enabled common platforms Exceed Growth

------

![](ex991clvtinvestorday074.jpg)

74 Life Sciences & Healthcare \| Pillars in action Enabling a top 5 medtech company to drive investment and performance decisions through comprehensive and contextual market intelligence insights Providing region specific disease landscape views for a top 10 pharmaceutical company, through cloud-based analytics platforms, integrating our solutions for a single source of truth Empowering digital transformation at a top 25 pharmaceutical company, across the regulatory affairs and intelligence workflows globally spanning 70+ countries

------

![](ex991clvtinvestorday075.jpg)

Brand Landscape Analyzer Embedded Intelligence Build use case-specific applications on top of our best- in-class content and search algorithms to offer a complete ecosystem of decision-support intelligence Patent and Trademark Services Integration Supporting deeper combined product value propositions through integrated services portfolio 75 Intellectual Property \| Returning to growth in underperforming areas Improving performance through value-add services Returning to market growth rates in Patent & Trademark Intelligence and Patent & Trademark Maintenance solutions Service Automation Leverage AI and automation in-house to increase operational efficiencies and deliver higher-value services to our customers Disrupt Search and Watch Services Combine AI-driven analytics and Trademark search expertise to deliver improved decision-making Derwent™ Patent Services Achieve Growth

------

![](ex991clvtinvestorday076.jpg)

FoundationIP™IPfolio™ 76 Intellectual Property \| Actioning our growth opportunity across high performing areas Accelerating the capture of market opportunities Driving growth and expanding SAM in high performing areas Patent and Trademark Offices Strengthen our partnerships with the top patent and trademark offices and expand to new emerging jurisdictions Innovation Intelligence Aligning academics, government policymakers, and corporates through a data-driven innovation strategy Best-in-class IP Management Strengthen position and enable growth using embedded insights, services integration and advanced technology capabilities, including blockchain Enabling a Connected IP Ecosystem Next-gen of IP filing, workflow and payment management to drive productivity and collaboration Connect Exceed Growth

------

![](ex991clvtinvestorday077.jpg)

77 Intellectual Property\| Pillars in action Supporting a Japanese technology corporation to effectively manage complex IP regulations through an integrated and localized software solution Partnering with an automotive manufacturer to inform R&D investment strategy through our patent and research intelligence solutions Bringing together our insights and tech-enabled services to support a European personal care corporation successfully manage and assess trademark risk

------

![](ex991clvtinvestorday078.jpg)

78 Investing across our growth levers to achieve and exceed market growth rates ~$25B SAM³ 6% Growth Rate >100B TAM³ 10% Growth Rate ~$2.7B Revenue¹ 3% Growth Rate² Growth Acceleration Framework Customer-centric go-to-market model Leverage interconnected data Insights and predictive analytics Business processes & decision support Trusted strategic partner 1 FY22 revenue. ² FY20PF-22A CAGR. ³ Clarivate analysis.

------

![](ex991clvtinvestorday079.jpg)

79 Our Financial Outlook 09

------

![](ex991clvtinvestorday080.jpg)

Financial objectives 80 Accelerate organic growth to market levels 1 Durable margin through the investment cycle 2 Attractive cash flow engine 3 Disciplined capital allocation 4 We are going to progressively improve our growth rate We are going to invest to catalyze growth in high potential areas We are going to generate more cash than we ever have We are going to deleverage and return to buy backs and accretive M&A

------

![](ex991clvtinvestorday081.jpg)

81 Financial evolution NYSE Listing FY19 Today FY22 Outlook FY25 Organic Growth 3% 3% ~6% Revenue $1.0B $2.7B ~$3.0B Adj. EBITDA 30% $0.3B 42% $1.1B ~43% $1.3B Adj. Diluted EPS $0.53 $0.85 ~$1.00 Free Cash Flow <$0.1B $0.3B ~$0.7B Net Leverage 5.4x 4.2x <3x +300 bps 3x +$1B 2x >10x (>2x) >2.5x +1200 bps +30₵ >2x (>1x) See the Appendix for a reconciliation of GAAP to Non-GAAP measures.

------

![](ex991clvtinvestorday082.jpg)

$305 ~ $500 27% 44% > 50% 15% 25% 35% 45% 55% 65% 2022A 2023P 2024E 2025E FCF Conversion 82 Improvement trajectory Revenue ($B) Adjusted Diluted EPS Free Cash Flow ($M) Adjusted EBITDA ($M)Revenue Expect organic growth acceleration to reach market growth levels by 2025. ~$3B revenue by 2025 as organic growth improves. USD expected to remain at current levels in long term projections Adj. EBITDA Durable profit margins to modestly expand each year Free Cash Flow Projecting substantial improvement in FCF conversion in 2023 on significantly lower one- time costs. ~$1.8B FCF generation in next three years See the Appendix for a reconciliation of GAAP to Non-GAAP measures. 2024E and 2025E reflect our long-term objectives. $0.85 $0.80 ~ $1.00 2022A 2023P 2024E 2025E $1,113 $1,130 41.8% 42.3% 2022A 2023P 2024E 2025E Adj EBITDA Adj EBITDA Margin +/- 0.5% +/- $0.05 ~10% CAGR +/- $50m ~ $1.8B FCF Generation + ~50 bps p.a. $2.7 $2.7 ~ $3.0 2.6% 3.25% 2022A 2023P 2024E 2025E Revenue, Net Organic Growth 4.5% 6.0% +/- 0.5% +/- 0.5% +/- 0.5%

------

![](ex991clvtinvestorday083.jpg)

83 Segment 1 Percentage of FY22 Clarivate revenue. Accelerate organic growth to market levels Achieving / exceeding market growth Close to market growth Underperforming market growth Key Academia & Government (Market Growth ~4%) Research and Analytics Content Aggregation Workflow Software Solutions ~48%¹ Intellectual Property (Market Growth ~6%) ~35%¹ Life Sciences & Healthcare (Market Growth ~10%) Research and Development Regulatory and Safety Commercialization ~17%¹ Patent and Trademark Intelligence Patent and Trademark Management Patent and Trademark Maintenance FY19-22 FY23 FY24 FY25

------

![](ex991clvtinvestorday084.jpg)

30% 38% 43% 42% ~42% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0% 45.0% 0 50 100 150 200 250 300 350 400 2019A 2020A 2021A 2022A 2023P 2024E 2025E 84 Durable margin through the investment cycle Investment in Margin Expansion M&A / Integration ($M) Margin Growth (%) Organic Revenue Growth (%) Payback Period: ~2 Years Payback Period: ~2.5 Years Growth Investment ($M) Investment in Organic Growth ~$500m¹ investment from 2019-2022 resulting in ~$300m of run rate synergy savings and double-digit margin expansion Expect to invest incremental $100-$150m² from 2023-25 to drive organic growth improvement of ~300bps, while maintaining healthy margins 3% Average Organic Revenue Growth (2019-22) ~3% ~6% +150 bps 1 Includes ~$240m transaction costs, ~$150m Restructuring and ~$100m of debt issuance and financing related costs. ² Includes ~$50m incremental capital investment and ~$80m opex investment in key initiatives to drive incremental growth.

------

![](ex991clvtinvestorday085.jpg)

-$73 -$10 2022A 2023P 2024E 2025E $64 $70 $252 $270 2022A 2023P 2024E 2025E Interest Taxes 85 Attractive cash flow engine One Time Costs ($M) Working Capital Change ($M) Capex ($M) Interest and Taxes ($M) $215 $40 2022A 2023P 2024E 2025E $203 $240 8% 9% 8% 2% 4% 6% 8% 10% 12% 14% 2022A 2023P 2024E 2025E % of Revenue One-Time Costs Expect minimal one-time costs in future as most of large M&A integration is complete Interest and Taxes Expect interest costs to decline as excess cash is used to de-lever. Cash taxes expected to remain ~$70m per annum Working Capital Modest working capital investment required to grow topline Capex Capital investments to increase to ~9% for next 2 years to propel growth and then reduce back to ~8% of sales 2024E and 2025E reflect our long-term objectives.

------

![](ex991clvtinvestorday086.jpg)

86 Disciplined capital allocation Organic investments to catalyze growth Enhance strategic value by prioritizing high ROI opportunities $1bn repurchase program authorized in early 2022 Highly selective investment criteria following period of major acquisitions Optimize capital structure Continue to prioritize deleveraging in 2023 and reduced floating rate exposure 1 2 Retain option to repurchase shares 3 M&A 4 2023 - 2025 2024 - 25 1 2 3 4

------

![](ex991clvtinvestorday087.jpg)

$5.1 $4.7 4x <4x 2022A 2023P 2024E 2025E Total Debt Net Leverage $252 $270 4x 4x 0.0 2.0 4.0 6.0 8.0 10.0 2022A 2023P 2024E 2025E Cash Interest Interest Coverage ¹ Debt maturity based on Dec 2022 actual debt balance. See the Appendix for a reconciliation of GAAP to Non-GAAP measures. 2024E and 2025E reflect our long-term objectives. ² De-levered WACD at Libor forward curve as of Dec 2025. 87 Continue to strengthen balance sheet and mitigate interest rate risk Total Debt / Net Leverage ($B) Debt Maturity ($B)¹ Interest Rate Mix Interest Coverage ($M) Deleveraging Anticipate <4x leverage by end of 2023 by utilizing FCF to repay floating rate debt Expect leverage to be <3x by 2025 with a balanced FCF allocation to deleverage and buy back shares Debt Structure Expect minimal floating rate debt exposure as excess cash is used to deleverage over the next 3 years No debt maturities or mandatory pre-payments for the next 3 years $2.5 $0.7 $0.9 $0.9 $0.8 2026 2027 2028 2029 Term Loans Notes Undrawn Revolver $0.8 Floating Rate Fixed Rate Today Deleveraged Outlook ~5.5% WACD ~5.0% WACD² <3x

------

![](ex991clvtinvestorday088.jpg)

88 SAM Growth¹~6% Average percentage points market indicators outperformed GDP² +8% ~80% Recurring revenue ¹Clarivate analysis. ² Avg. performance across three market indicators during 2008-09. ³ FY22 renewal rate, subscription products. Renewal rate³>90% Multiple reinforcing dynamics combine, presenting a compelling opportunity to drive profitable and sustainable growth Secular Growth Markets Economically Insulated • x Our markets are expanding, driven by innovation with long runway for growth Resilient markets which outperform in periods of economic downturn Industry gold standard solutions embedded in customer workflows Recurring information services compounder poised to accelerate organic growth and financial returns Mission Critical Solutions Robust Business Model

------

![](ex991clvtinvestorday089.jpg)

89 Q&A Session 10

------

![](ex991clvtinvestorday090.jpg)

90 Jonathan Gear Chief Executive Officer Closing Remarks

------

![](ex991clvtinvestorday091.jpg)

91 Accelerated compound returns driven by reinvestment into high-potential growth areas Shared Content Shared Technology Shared Commercial Channels Operating Model Driving Accountability and Leveraging Shared Scale Scale Across Core Markets Secular Growth Markets Significant Operating Leverage Attractive Cash Flow Engine Disciplined Capital Allocation ~80% Recurring Revenue ~50% FCF Conversion >90% Renewal Rates >40% Profit Margin

------

![](ex991clvtinvestorday092.jpg)© 2022 Clarivate. All rights reserved. Republication or redistributionof Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license. Thank you 3

------

## Exhibit 99.2

![](ex992clvtinvestordayappe001.jpg)

1 Appendix

------

![](ex992clvtinvestordayappe002.jpg)

2 Presentation of Certain Non-GAAP Financial Measures This presentation contains financial measures which have not been calculated in accordance with generally accepted accounting principles in the United States of America ("US GAAP"), including Organic/Inorganic Revenues, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Diluted EPS, Free Cash Flow and Adjusted Free Cash Flow because they are a basis upon which our management assesses our performance, and we believe they reflect the underlining trends and indicators of our business. Organic/Inorganic Revenues Organic revenues illustrates growth in businesses owned by the Company after twelve months, at constant currency. Inorganic revenues illustrates growth in the business via acquisitions and divestitures. Adjusted EBITDA Adjusted EBITDA represents net loss before the provision for income taxes, depreciation and amortization, interest income and expense adjusted to exclude the acquisition or disposal-related transaction costs (such costs include net income from continuing operations before provision for income taxes, depreciation and amortization and interest income and expense from divestitures), share-based compensation, mandatory convertible preferred share dividend expense, unrealized foreign currency gains (losses), transformational and restructuring expenses, acquisition-related adjustments to deferred revenues, non-operating income or expense, the impact of certain non-cash, mark-to-market adjustments on financial instruments, legal settlements, goodwill impairment and other items that are included in net income for the period that the Company does not consider indicative of its ongoing operating performance and certain unusual items impacting results in a particular period. In evaluating Adjusted EBITDA, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the included adjustments. The Company's presentation of Adjusted EBITDA should not be construed as an inference that the Company's future results will be unaffected by any of the adjusted items, or that the Company's projections and estimates will be realized in their entirety or at all.

------

![](ex992clvtinvestordayappe003.jpg)

3 Presentation of Certain Non-GAAP Financial Measures Adjusted EBITDA The use of Adjusted EBITDA instead of US GAAP has limitations as an analytical tool, and you should not consider Adjusted EBITDA in isolation, or as a substitute for analysis of the Company's results of operations and operating cash flows as reported under US GAAP. For example, Adjusted EBITDA does not reflect: – the Company's cash expenditures or future requirements for capital expenditures – changes in, or cash requirements for, the Company's working capital needs – interest expense, or the cash requirements necessary to service interest or principal payments, on the Company's debt – any cash income taxes that the Company may be required to pay – any cash requirements for replacements of assets that are depreciated or amortized over their estimated useful lives and may have to be replaced in the future – all non-cash income or expense items that are reflected in the Company's statements of cash flows The Company's definition of and method of calculating Adjusted EBITDA may vary from the definitions and methods used by other companies when calculating Adjusted EBITDA, which may limit their usefulness as comparative measures. The Company prepared the information included in this presentation based upon available information and assumptions and estimates that it believes are reasonable. The Company cannot assure you that its estimates and assumptions will prove to be accurate. Adjusted EBITDA Margin Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Revenues, net plus the impact of the deferred revenue purchase accounting adjustments relating to acquisitions prior to 2021.

------

![](ex992clvtinvestordayappe004.jpg)

4 Presentation of Certain Non-GAAP Financial Measures Adjusted Net Income and Adjusted Diluted EPS We use Adjusted Net Income and Adjusted Diluted Earnings Per Share ("Adjusted Diluted EPS") in our analysis of the financial performance of the Company. We believe Adjusted Net Income and Adjusted Diluted EPS are meaningful measures of the performance of the Company because they adjust for items that do not directly affect our ongoing operating performance in the period. Adjusted Net Income is calculated using Net income (loss), adjusted to exclude acquisition or disposal-related transaction costs (such costs include net income from continuing operations before the provision for income taxes, depreciation and amortization and interest income and expense from the divested business), amortization related to acquired intangible assets, share-based compensation, mandatory convertible preferred share dividend expense, unrealized foreign currency gains/(losses), transformational and restructuring expenses, acquisition-related adjustments to deferred revenues, the impact of certain non-cash mark-to-market adjustments on financial instruments, interest on debt held in escrow, goodwill impairment and other items that are included in net income for the period that the Company does not consider indicative of its ongoing operating performance and certain unusual items impacting results in a particular period, and the income tax impact of any adjustments. We calculate Adjusted Diluted EPS by using Adjusted Net Income divided by diluted weighted average shares for the period. Free Cash Flow We use Free Cash Flow in our operational and financial decision-making and believe Free Cash Flow is useful to investors because similar measures are frequently used by securities analysts, investors, ratings agencies and other interested parties to evaluate the ability of companies to service their debt. Free Cash Flow is calculated using net cash provided by operating activities, less capital expenditures.

------

![](ex992clvtinvestordayappe005.jpg)

5 Reconciliation of Non-GAAP Financial Measures Net Loss to Adjusted EBITDA Year Ended December 31, (in millions); (unaudited) 2022 Net loss attributable to ordinary shares $(4,035.6) Dividends on preferred shares 75.4 Net loss (3,960.2) (Benefit) provision for income taxes (28.9) Interest expense and amortization of debt discount, net 270.3 EBIT (3,718.8) Depreciation and amortization 710.5 Deferred revenues adjustment(1) 1.0 Transaction related costs(2) 14.2 Share-based compensation expense 102.2 Gain on sale of divestitures(3) (278.5) Restructuring and impairment(4) 66.7 Goodwill impairment 4,449.1 Mark-to-market (gain) loss on financial instruments(5) (206.8) Other(6) (26.9) Adjusted EBITDA $1,112.7 Adjusted EBITDA Margin 41.8 % Descriptions Adjusted EBITDA adjustments 1. Reflects the deferred revenues adjustment made as a result of purchase accounting prior to the adoption of ASU No. 2021-08, "Accounting for Contract Assets and Contract Liabilities from Contracts with Customers". This guidance was applied retrospectively to all business combinations for which the acquisition date occurs during or subsequent to 2021. 2. Includes costs incurred to complete business combination transactions, including acquisitions, dispositions and capital market activities and include advisory, legal, and other professional and consulting costs. 2021 also includes the mark-to-market adjustment (gains) on the contingent stock consideration associated with the CPA Global and DRG acquisitions. 3. 2022 represents the net gain from the sale of the MarkMonitor Domain Management business. 2020 represents the net gain from sale of certain assets and liabilities of the Techstreet business. 4. Primarily reflects costs related to restructuring and impairment associated with the One Clarivate, ProQuest and CPA Global restructuring programs. 5. Reflects mark-to-market adjustments on the Private Placement Warrants under ASC 815, Derivatives and Hedging. Warrant instruments that do not meet the criteria to be considered indexed to an entity's own stock shall be initially classified as a liability at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash. In periods subsequent to issuance, changes in the estimated fair value of the liabilities are reported through earnings. 6. Primarily reflects the net impact of foreign exchange gains and losses related to the re- measurement of balances and other items that do not reflect our ongoing operating performance. The 2020 detail also includes costs incurred in connection with and after our separation from Thomson Reuters in 2016 relating to the implementation of our standalone company infrastructure and related cost-savings initiatives.

------

![](ex992clvtinvestordayappe006.jpg)

Year Ended December 31, 2022 (in millions, except per share amounts); (unaudited) Amount Per Share Net loss attributable to ordinary shares, diluted $(4,231.5) $(6.24) Change in fair value of private placement warrants 195.9 0.29 Net income (loss) attributable to ordinary shares (4,035.6) (5.95) Dividends on preferred shares 75.4 0.11 Net loss (3,960.2) (5.84) Deferred revenues adjustment(1) 1.0 — Transaction related costs(2) 14.2 0.02 Share-based compensation expense 102.2 0.15 Amortization related to acquired intangible assets 579.6 0.85 Restructuring and impairment(3) 66.7 0.10 Goodwill impairment 4,449.1 6.56 Mark-to-market (gain) loss on financial instruments(4) (206.8) (0.30) Interest on debt held in escrow(5) — — Other(6) (305.4) (0.52) Income tax impact of related adjustments (112.4) (0.17) Adjusted net income and Adjusted Diluted EPS $628.0 $0.85 Adjusted weighted average ordinary shares (Diluted) 737.1 6 Reconciliation of Non-GAAP Financial Measures (YTD) Net Loss and Net Loss Per Share to Adjusted Net Income and Adjusted Diluted EPS Descriptions Adjusted Net Income and Adjusted Diluted EPS adjustments 1. Reflects the deferred revenues adjustment made as a result of purchase accounting prior to the adoption of ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. In the fourth quarter of 2021, Clarivate adopted ASU No. 2021-08 which allows an acquirer to account for the related revenue contracts in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. This guidance was applied retrospectively to all business combinations for which the acquisition date occurs during or subsequent to 2021. 2. Includes costs incurred to complete business combination transactions, which was comprised of acquisitions, dispositions and capital market activities, as well as advisory, legal, and other professional and consulting costs. 2021 also includes the mark-to-market adjustment (gains) on the contingent stock consideration associated with the CPA Global and DRG acquisitions. 3. Primarily reflects costs related to restructuring and impairment associated with the One Clarivate, ProQuest and CPA Global restructuring programs. 4. Reflects mark-to-market adjustments on financial instruments under ASC 815, Derivatives and Hedging. Warrant instruments that do not meet the criteria to be considered indexed to an entity's own stock shall be initially classified as a liability at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash. In periods subsequent to issuance, changes in the estimated fair value of the liabilities are reported through earnings. 5. Reflects interest expense incurred on secured and unsecured notes issued in 2021, while held in escrow pending the completion of the acquisition of ProQuest on December 1, 2021. Clarivate used the net proceeds to finance a portion of the purchase price and therefore considers this interest expense as part of the transaction costs associated with the acquisition. 6. 2022 includes the $(278.5) net gain from the sale of the MarkMonitor Domain Management business. The remaining amount primarily includes the net impact of foreign exchange gains and losses related to the re-measurement of balances and other items that do not reflect our ongoing operating performance.

------

![](ex992clvtinvestordayappe007.jpg)

7 Reconciliation of Non-GAAP Financial Measures Net Cash Provided By Operating Activities to Free Cash Flow and Adjusted Free Cash Flow Year Ended December 31, (in millions); (unaudited) 2022 Net cash provided by operating activities $509.3 Capital expenditures (202.9) Free cash flow $306.4

------

![](ex992clvtinvestordayappe008.jpg)

8 Reconciliation of Non-GAAP Financial Measures Adjusted EBITDA Revenues, Net Variance Increase / (Decrease) Percentage of Factors Increase / (Decrease) Year Ending December 31, Total Variance (Dollars) Total Variance (Percentage) Acquisitions Disposal FX Impact Organic (in millions) 2023 Outlook mid-point 2022 Revenues, Net $2,680 $2,660 $20 0.8% — % (2.4)% (0.1)% 3.3% The following table presents our calculation of Revenues, net for the FY2023 outlook: Year Ending December 31, 2023 (Forecasted) Low High (in millions) Net loss attributable to ordinary shares $(207) $(147) Dividends on preferred shares(1) 75 75 Net loss (131) (71) Provision for income taxes 70 70 Depreciation and amortization 720 720 Interest expense and amortization of debt discount, net 286 286 Restructuring and impairment(2) 25 25 Share-based compensation expense 130 130 Adjusted EBITDA $1,100 $1,160 Adjusted EBITDA margin 42.0 % 42.5 % Descriptions 1. Dividends on our mandatory convertible preferred shares ("MCPS") are payable quarterly at an annual rate of 5.25% of the liquidation preference of $100 per share. For the purposes of calculating net loss attributable to Clarivate, we have excluded the accrued and anticipated MCPS dividends. 2. Primarily reflects restructuring costs expected to be incurred in 2023 associated with the ProQuest acquisition restructuring program. The following table presents our calculation of Adjusted EBITDA for the FY2023 outlook and reconciles this measure to our Net income (loss) for the same period:

------

![](ex992clvtinvestordayappe009.jpg)

9 Reconciliation of Non-GAAP Financial Measures Net Income (Loss) Per Fully Diluted Weighted Shares Outstanding to Adjusted Diluted EPS The following table presents our calculation of Adjusted Diluted EPS for the FY2023 outlook and reconciles this measure to our Net income (loss) per share for the same period: Descriptions 1. Dividends on our mandatory convertible preferred shares ("MCPS") are payable quarterly at an annual rate of 5.25% of the liquidation preference of $100 per share. For the purposes of calculating net loss attributable to Clarivate, we have excluded the accrued and anticipated MCPS dividends. 2. Primarily reflects restructuring costs expected to be incurred in 2023 associated with the ProQuest acquisition restructuring program. 3. For the purposes of calculating adjusted earnings per share, the Company has excluded the accrued and anticipated MCPS dividends and assumed the "if-converted" method of share dilution. Year Ending December 31, 2023 (Forecasted) Low High Per Share Per Share Net loss attributable to ordinary shares $(0.28) $(0.20) Dividends on preferred shares(1) 0.10 0.10 Net loss (0.18) (0.10) Restructuring and impairment(2) 0.03 0.03 Share-based compensation expense 0.18 0.18 Amortization related to acquired intangible assets 0.77 0.77 Other (0.01) 0.01 Income tax impact of related adjustments (0.05) (0.05) Adjusted Diluted EPS $0.75 $0.85 Weighted average ordinary shares (Diluted)(3) 740 million

------

![](ex992clvtinvestordayappe010.jpg)

10 Reconciliation of Non-GAAP Financial Measures Net Cash Provided by Operating Activities to Free Cash Flow The following table presents our calculation of Free cash flow for the FY2023 outlook and reconciles this measure to our Net cash provided by operating activities for the same period: Year Ending December 31, 2023 (Forecasted) (in millions) Low High Net cash provided by operating activities $690 $790 Capital expenditures (240) (240) Free cash flow $450 $550

------